Gary O'Neill
Hoofd Techniek/Wetenschap/O&O bij Abide Therapeutics, Inc.
Profiel
Gary O'Neill is currently the Chief Scientific Officer at Abide Therapeutics, Inc. He completed his undergraduate degree at McGill University and his doctorate at the University of British Columbia.
Actieve functies van Gary O'Neill
| Bedrijven | Functie | Begin |
|---|---|---|
Abide Therapeutics, Inc.
 Abide Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA. | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van Gary O'Neill
| McGill University | Undergraduate Degree |
| University of British Columbia | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 1 |
|---|---|
Abide Therapeutics, Inc.
Abide Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA. | Health Technology |
